- Home
- Equipment
- switzerland
- pharma to develop
Show results for
Refine by
Pharma To Develop Equipment Supplied In Switzerland
6 equipment items found
by:CIS Pharma AG based inBubendorf, SWITZERLAND
CIS Pharma has developed the new standard of bio-inspired contact lens care solutions for cleaning, disinfection and storage of silicone hydrogel contact lenses. Compared to market leaders, the product shows superior disinfecting power. In addition, the product offers an innovative comfort-agent complex that delivers an unsurpassed amount of hyaluronic acid to ...
by:T3 Pharmaceuticals AG based inBasel, SWITZERLAND
T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria selectively target solid tumors, where they deliver chosen protein payloads into the ...
by:CIS Pharma AG based inBubendorf, SWITZERLAND
CIS Pharma offers a platform of different eye drop dispenser technologies designed for preservative-free drug formulations as eye-drops or as a spray. Devices to control eye-lids as well as digital technology to monitor drug dispense are available to improve the compliance of patients. The platform is a result of our expertise in ophthalmology: since the early eighties CIS ...
Manufactured by:Cerbios-Pharma SA based inBarbengo – Lugano, SWITZERLAND
Cerbios supplies different HPAPI derivatives of Vitamin D3 worldwide. Cerbios has been manufacturing and commercialising HPAPI derivatives of vitamin D3 since 1993 and is continuously working to develop new products and improve their quality. Calcipotriol was the first vitamin D analogue which was developed for pharmaceutical application and is now formulated in different pharmaceutical forms, ...
by:CIS Pharma AG based inBubendorf, SWITZERLAND
RNA interference (RNAi) is a mechanism used to defend against external invasion. Oligo- and poly-nucleotide based RNAi therapeutics comprise a high clinical potential for unmet medical diseases and are seen as promising approach to combat a number of different indications including oncology, genetic disorders, auto-immune disorders, orphan diseases and viral ...
by:CIS Pharma AG based inBubendorf, SWITZERLAND
CIS Pharma develops novel antibody-drug- conjugates (ADCs) based on our proprietary polymer carrier platform. Our polymers serve as carriers that are loaded with cytotoxic drugs, radioisotopes or other active entities. The carrier together with its cargo is conjugated to a target-specific antibody using site-directed linker chemistry, different from the linker ...